Shopping Cart 0
Cart Subtotal
USD 0

Genmab AS (GEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company's marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Genmab's products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS (GEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genmab A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10

Genmab A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Genmab A/S, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Genmab Acquires Antibody Assets from iDD Biotech 13

Partnerships 14

Mabimmune and Genmab Enter into Research Collaboration 14

Genmab Enters into Co-Development Agreement with BioNTech 15

BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 16

Genmab Enters into Research Agreement with Seattle Genetics 17

Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 18

MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 19

Genmab Enters Into Co-Development Agreement With ADC Therapeutics 20

Genmab Enters into Co-Development Agreement with ADC Therapeutics 21

Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 22

Licensing Agreements 23

Genmab Enters into Licensing Agreement with Immatics Biotechnologies 23

Genmab Enters into Licensing Agreement with Gilead Sciences 24

Novo Nordisk Expands Licensing Agreement with Genmab 25

Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 26

Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 27

Genmab Expands Licensing Agreement With Janssen Biotech 29

Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 30

Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 31

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 32

Equity Offering 33

Genmab Raises USD1.2 Million in Private Placement of Shares up on Exercise of Warrants 33

Genmab to Raise USD4.8 Million in Private Placement of Shares upon Exercise of Warrants 34

Genmab Completes Private Placement of Shares for USD181.3 Million 35

Genmab Completes Private Placement Of Shares For USD 2 Million Upon Exercise Of Warrants 36

Genmab Completes Private Placement Of Shares For USD 5 Million Upon Exercise Of Warrants 37

Asset Transactions 38

Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For USD 10 Million 38

Acquisition 39

Meditor European Master Fund Sells Its Stake In Genmab 39

Genmab A/S-Key Competitors 40

Genmab A/S-Key Employees 41

Genmab A/S-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 43

Financial Announcements 43

May 08, 2018: Genmab: Interim Report First Quarter 2018 43

Feb 21, 2018: Genmab 2017 Annual Report 44

Nov 08, 2017: Genmab Announces Financial Results for the First Nine Months of 2017 46

Aug 09, 2017: Genmab Announces Financial Results for the First Half of 2017 47

May 10, 2017: Genmab Announces Financial Results for the First Quarter of 2017 48

Feb 22, 2017: Genmab 2016 Annual Report 53

Jan 24, 2017: Genmab reports net sales for DARZALEX in 2016 54

Corporate Communications 55

Feb 08, 2017: Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer 55

Product News 56

06/29/2018: HuMax-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics 56

05/17/2018: Genmab Announces to Present Abstract on CD3xCD20 at 23rd EHA Annual Congress 57

04/20/2017: Genmab To Present Poster Presentations On HuMax-AXL-ADC at 2017 ASCO Annual Meeting 58

Other Significant Developments 59

Dec 11, 2017: Genmab's 2017 R&D Update 59

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Genmab A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genmab A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genmab A/S, Deals By Therapy Area, 2012 to YTD 2018 9

Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10

Genmab A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Genmab Acquires Antibody Assets from iDD Biotech 13

Mabimmune and Genmab Enter into Research Collaboration 14

Genmab Enters into Co-Development Agreement with BioNTech 15

BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 16

Genmab Enters into Research Agreement with Seattle Genetics 17

Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 18

MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 19

Genmab Enters Into Co-Development Agreement With ADC Therapeutics 20

Genmab Enters into Co-Development Agreement with ADC Therapeutics 21

Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 22

Genmab Enters into Licensing Agreement with Immatics Biotechnologies 23

Genmab Enters into Licensing Agreement with Gilead Sciences 24

Novo Nordisk Expands Licensing Agreement with Genmab 25

Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 26

Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 27

Genmab Expands Licensing Agreement With Janssen Biotech 29

Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 30

Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 31

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 32

Genmab Raises USD1.2 Million in Private Placement of Shares up on Exercise of Warrants 33

Genmab to Raise USD4.8 Million in Private Placement of Shares upon Exercise of Warrants 34

Genmab Completes Private Placement of Shares for USD181.3 Million 35

Genmab Completes Private Placement Of Shares For USD 2 Million Upon Exercise Of Warrants 36

Genmab Completes Private Placement Of Shares For USD 5 Million Upon Exercise Of Warrants 37

Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For USD 10 Million 38

Meditor European Master Fund Sells Its Stake In Genmab 39

Genmab A/S, Key Competitors 40

Genmab A/S, Key Employees 41

Genmab A/S, Subsidiaries 42

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Genmab AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company's marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Genmab's products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS (GEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genmab A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10

Genmab A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Genmab A/S, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Genmab Acquires Antibody Assets from iDD Biotech 13

Partnerships 14

Mabimmune and Genmab Enter into Research Collaboration 14

Genmab Enters into Co-Development Agreement with BioNTech 15

BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 16

Genmab Enters into Research Agreement with Seattle Genetics 17

Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 18

MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 19

Genmab Enters Into Co-Development Agreement With ADC Therapeutics 20

Genmab Enters into Co-Development Agreement with ADC Therapeutics 21

Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 22

Licensing Agreements 23

Genmab Enters into Licensing Agreement with Immatics Biotechnologies 23

Genmab Enters into Licensing Agreement with Gilead Sciences 24

Novo Nordisk Expands Licensing Agreement with Genmab 25

Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 26

Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 27

Genmab Expands Licensing Agreement With Janssen Biotech 29

Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 30

Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 31

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 32

Equity Offering 33

Genmab Raises USD1.2 Million in Private Placement of Shares up on Exercise of Warrants 33

Genmab to Raise USD4.8 Million in Private Placement of Shares upon Exercise of Warrants 34

Genmab Completes Private Placement of Shares for USD181.3 Million 35

Genmab Completes Private Placement Of Shares For USD 2 Million Upon Exercise Of Warrants 36

Genmab Completes Private Placement Of Shares For USD 5 Million Upon Exercise Of Warrants 37

Asset Transactions 38

Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For USD 10 Million 38

Acquisition 39

Meditor European Master Fund Sells Its Stake In Genmab 39

Genmab A/S-Key Competitors 40

Genmab A/S-Key Employees 41

Genmab A/S-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 43

Financial Announcements 43

May 08, 2018: Genmab: Interim Report First Quarter 2018 43

Feb 21, 2018: Genmab 2017 Annual Report 44

Nov 08, 2017: Genmab Announces Financial Results for the First Nine Months of 2017 46

Aug 09, 2017: Genmab Announces Financial Results for the First Half of 2017 47

May 10, 2017: Genmab Announces Financial Results for the First Quarter of 2017 48

Feb 22, 2017: Genmab 2016 Annual Report 53

Jan 24, 2017: Genmab reports net sales for DARZALEX in 2016 54

Corporate Communications 55

Feb 08, 2017: Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer 55

Product News 56

06/29/2018: HuMax-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics 56

05/17/2018: Genmab Announces to Present Abstract on CD3xCD20 at 23rd EHA Annual Congress 57

04/20/2017: Genmab To Present Poster Presentations On HuMax-AXL-ADC at 2017 ASCO Annual Meeting 58

Other Significant Developments 59

Dec 11, 2017: Genmab's 2017 R&D Update 59

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Genmab A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Genmab A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Genmab A/S, Deals By Therapy Area, 2012 to YTD 2018 9

Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10

Genmab A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Genmab Acquires Antibody Assets from iDD Biotech 13

Mabimmune and Genmab Enter into Research Collaboration 14

Genmab Enters into Co-Development Agreement with BioNTech 15

BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 16

Genmab Enters into Research Agreement with Seattle Genetics 17

Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 18

MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 19

Genmab Enters Into Co-Development Agreement With ADC Therapeutics 20

Genmab Enters into Co-Development Agreement with ADC Therapeutics 21

Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 22

Genmab Enters into Licensing Agreement with Immatics Biotechnologies 23

Genmab Enters into Licensing Agreement with Gilead Sciences 24

Novo Nordisk Expands Licensing Agreement with Genmab 25

Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 26

Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 27

Genmab Expands Licensing Agreement With Janssen Biotech 29

Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 30

Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 31

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 32

Genmab Raises USD1.2 Million in Private Placement of Shares up on Exercise of Warrants 33

Genmab to Raise USD4.8 Million in Private Placement of Shares upon Exercise of Warrants 34

Genmab Completes Private Placement of Shares for USD181.3 Million 35

Genmab Completes Private Placement Of Shares For USD 2 Million Upon Exercise Of Warrants 36

Genmab Completes Private Placement Of Shares For USD 5 Million Upon Exercise Of Warrants 37

Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For USD 10 Million 38

Meditor European Master Fund Sells Its Stake In Genmab 39

Genmab A/S, Key Competitors 40

Genmab A/S, Key Employees 41

Genmab A/S, Subsidiaries 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Genmab AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.